The Effects of Extracellular Matrix Proteins on Neutrophil-Endothelial Interaction - A Roadway To Multiple Therapeutic Opportunities

Yale Journal of Biology and Medicine

Volumn 85, Issue 2, 2012, Pages 167-185

  Padmanabhan, Jagannath ^a   Gonzalez, Anjelica L ^a  

^a Yale University   (United States)

Author keywords

Atherosclerosis; COPD; Endothelial cells; Extracellular matrix; Inflammation; Neutrophils; Reactive oxygen species; Tumor

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; CD31 ANTIGEN; CELL PROTEIN; COLLAGEN; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LAMININ; LOW DENSITY LIPOPROTEIN; MINDIN PROTEIN; NEUTROPHIL COLLAGENASE; NITRIC OXIDE; PEROXYNITRITE; SCLEROPROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE;

ATHEROSCLEROSIS; BIOMEDICAL ENGINEERING; CELL INTERACTION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE MODEL; DOWN REGULATION; ENDOTHELIUM; HUMAN; INFLAMMATORY DISEASE; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TUMOR GROWTH; UPREGULATION; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GRANULOCYTE FUNCTION; IMMUNE RESPONSE; PATHOLOGICAL ANATOMY; PROTEIN MODIFICATION; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; CELL COMMUNICATION; CYTOKINES; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84863488222     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Schmidt EP, Lee WL, Zemans RL, Yamashita C, Downey GP. On, around, and through: neutrophil-endothelial interactions in innate immunity. Physiology. 2011;26(5):334-47.
2. Seely AJ, Pascual JL, Christou NV. Science review: Cell membrane expression (connectivity) regulates neutrophil delivery, function and clearance. Crit Care. 2003;7(4):291-307.
3. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-89.
4. Gonzalez-Simon AL, Eniola-Adefeso O. Engineering Biomaterials for Regenerative Medicine: Host Response to Biomaterials. Cambridge: Springer; 2012. p. 143-58.
5. Hickey MJ, Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol. 2009;9(5):364-75.
6. Neufert C, Pai RK, Noss EH, Berger M, Boom WH, Harding CV. Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation. J Immunol. 2001;167(3):1542-9.
7. Eruslanov E, Lyadova I, Kondratieva T, Majorov K, Scheglov I, Orlova M, et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun. 2005;73(3):1744-53.
8. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation. 2009;120(20):2012-24.
9. Gonzalez AL, El-Bjeirami W, West JL, McIntire LV, Smith CW. Transendothelial migration enhances integrin-dependent human neutrophil chemokinesis. J Leukoc Biol. 2007;81(3):686-95.
10. Kettritz R, Xu YX, Kerren T, Quass P, Klein JB, Luft FC, et al. Extracellular matrix regulates apoptosis in human neutrophils. Kidney Int. 1999;55(2):562-71.
11. Luscinskas FW, Brock AF, Arnaout MA, Gimbrone MA, Jr. Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol. 1989;142(7):2257-63.
12. Wang S, Voisin MB, Larbi KY, Dangerfield J, Scheiermann C, Tran M, et al. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J Exp Med. 2006;203(6):1519-32.
13. Poduval P, Sillat T, Virtanen I, Dabagh M, Konttinen YT. Immigration check for neutrophils in RA lining: laminin alpha5 low expression regions act as exit points. Scand J Rheumatol. 2010;39(2):132-40.
14. Voisin MB, Probstl D, Nourshargh S. Venular basement membranes ubiquitously express matrix protein low-expression regions: characterization in multiple tissues and remodeling during inflammation. Am J Pathol. 2010;176(1):482-95.
15. Borgquist JD, Quinn MT, Swain SD. Adhesion to extracellular matrix proteins modulates bovine neutrophil responses to inflammatory mediators. J Leukoc Biol. 2002;71(5):764-74.
16. Anceriz N, Vandal K, Tessier PA. S100A9 mediates neutrophil adhesion to fibronectin through activation of beta2 integrins. Biochem Biophys Res Commun. 2007;354(1):84-9.
17. Tortorella C, Piazzolla G, Spaccavento F, Vella F, Pace L, Antonaci S. Regulatory role of extracellular matrix proteins in neutrophil respiratory burst during aging. Mech Ageing Dev. 2000;119(1-2):69-82.
18. Gonzalez AL, West JL, McIntire LV, Smith CW. ECM interactions with neutrophil inte-grins regulate cell activity: An engineering approach to studying cell motility in inflammation. FASEB J. 2006;20(5):A1080.
19. Gonzalez AL, Gobin AS, West JL, McIntire LV, Smith CW. Integrin interactions with immobilized peptides in polyethylene glycol diacrylate hydrogels. Tissue Eng. 2004;10(11-12):1775-86.
20. Ginis I, Faller DV. Protection from apoptosis in human neutrophils is determined by the surface of adhesion. Am J Physiol. 1997;272(1 Pt 1):C295-309.
21. Woodfin A, Voisin MB, Nourshargh S. Recent developments and complexities in neutrophil transmigration. Curr Opin Hematol. 2010;17(1):9-17.
22. Vanderlaan PA, Reardon CA. Thematic review series: the immune system and atherogenesis. The unusual suspects:an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res. 2005;46(5):829-38.
23. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J Cell Mol Med. 2005;9(1):3-10.
24. Henriksen PA, Sallenave JM. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int J Biochem Cell Biol. 2008;40(6-7):1095-100.
25. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411-6.
26. Houghton AM. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle. 2010;9(9):1732-7.
27. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31(6):1334-56.
28. Kumar SD, Krishnamurthy K, Manikandan J, Pakeerappa PN, Pushparaj PN. Deciphering the key molecular and cellular events in neutrophil transmigration during acute inflammation. Bioinformation. 2011;6(3):111-4.
29. Alves-Filho JC, de Freitas A, Spiller F, Souto FO, Cunha FQ. The role of neutrophils in severe sepsis. Shock. 2008;30(Suppl 1):3-9.
30. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 1983;67(5):1016-23.
31. Davies EV, Hallett MB. Cytosolic Ca2+ signalling in inflammatory neutrophils: implications for rheumatoid arthritis (Review). Int J Mol Med. 1998;1(2):485-90.
32. Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med. 2006;203(4):837-42.
33. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488-96.
34. Bini A, Kudryk B, Numano F, Wissler R. Fibrinogen in human atherosclerosis. Atherosclerosis III: Recent Advances in Atherosclerosis Research. Ann NY Acad Sci. 1995;748:461-73.
35. Bdeir K, Cane W, Canziani G, Chaiken I, Weisel J, Koschinsky ML, et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood. 1999;94(6):2007-19.
36. Chavakis T, Cines DB, Rhee JS, Liang OD, Schubert U, Hammes HP, et al. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. Faseb J. 2004;18(11):1306-8.
37. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4(2):197-250.
38. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94(6):2493-503.
39. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA. 1991;88(18):8154-8.
40. Ionita MG, van den Borne P, Catanzariti LM, Moll FL, de Vries JP, Pasterkamp G, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol. 2010;30(9):1842-8.
41. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26(1):136-42.
42. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85(1):1-31.
43. Kennett EC, Rees MD, Malle E, Hammer A, Whitelock JM, Davies MJ. Peroxynitrite modifies the structure and function of the extracellular matrix proteoglycan perlecan by reaction with both the protein core and the heparan sulfate chains. Free Radic Biol Med. 2010;49(2):282-93.
44. Wang W, Sawicki G, Schulz R. Peroxynitriteinduced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 2002;53(1):165-74.
45. Akhtar K, Broekelmann TJ, Song H, Turk J, Brett TJ, Mecham RP, et al. Oxidative modifications of the C-terminal domain of tropoelastin prevent cell binding. J Biol Chem. 2011;286(15):13574-82.
46. Sohn HY, Krotz F, Zahler S, Gloe T, Keller M, Theisen K, et al. Crucial role of local peroxynitrite formation in neutrophil-induced endothelial cell activation. Cardiovasc Res. 2003;57(3):804-15.
47. Lefer DJ, Scalia R, Campbell B, Nossuli T, Hayward R, Salamon M, et al. Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J Clin Invest. 1997;99(4):684-91.
48. Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ, Schwartz MA. The subendothelial extracellular matrix modulates NFkappaB activation by flow: a potential role in atherosclerosis. J Cell Biol. 2005;169(1):191-202.
49. Nievelstein-Post P, Mottino G, Fogelman A, Frank J. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Aterioscler Thromb. 1994;14(7):1151-61.
50. Semple SJ, McKune AJ. Alpha1-Antitrypsin: Anti-inflammatory roles in exercise and atherosclerosis. African Journal of Biochemistry Research. 2011;5(5):143-7.
51. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-74.
52. Plenz GA, Deng MC, Robenek H, Volker W. Vascular collagens: spotlight on the role of type VIII collagen in atherogenesis. Atherosclerosis. 2003;166(1):1-11.
53. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104(16):1899-904.
54. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003;10(5):267-74.
55. Roh JD, Sawh-Martinez R, Brennan MP, Jay SM, Devine L, Rao DA, et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci USA. 2010;107(10):4669-74.
56. Henson PM, Vandivier RW. The matrix degrades, neutrophils invade. Nat Med. 2006;12(3):280-1.
57. Senior RM, Hinek A, Griffin GL, Pipoly DJ, Crouch EC, Mecham RP. Neutrophils Show Chemotaxis to Type-Iv Collagen and Its 7s Domain and Contain a 67-Kd Type-Iv Collagen Binding-Protein with Lectin Properties. Am J Respir Cell Mol Biol. 1989;1(6):479-87.
58. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med. 2006;12(3):317-23.
59. Vlahos R, Wark PAB, Anderson GP, Bozinovski S. Glucocorticosteroids Differentially Regulate MMP-9 and Neutrophil Elastase in COPD. PLoS ONE. 2012;7(3):e33277.
60. Lucas SD, Costa E, Guedes RC, Moreira R. Targeting COPD: Advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev. 2011 June 16 [Epub ahead of print].
61. Peinado VI, Barbera JA, Ramirez J, Gomez FP, Roca J, Jover L, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol. 1998;274(6 Pt 1):L908-13.
62. Cella G, Saetta M, Baraldo S, Turato G, Papi A, Casoni G, et al. Endothelial cell activity in chronic obstructive pulmonary disease without severe pulmonary hypertension. Clin Appl Thromb Hemost. 2005;11(4):435-40.
63. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3 Pt 1):998-1002.
64. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56(4):515-48.
65. Kanazawa H, Shiraishi S, Hirata K, Yoshikawa J. Imbalance between levels of nitrogen oxides and peroxynitrite inhibitory activity in chronic obstructive pulmonary disease. Thorax. 2003;58(2):106-9.
66. Liu P, Xu B, Quilley J, Wong PY. Peroxynitrite attenuates hepatic ischemia-reperfusion injury. Am J Physiol Cell Physiol. 2000;279(6):C1970-7.
67. Zhao S, Zhang Y, Gu Y, Lewis DF, Wang Y. Heme oxygenase-1 mediates up-regulation of adhesion molecule expression induced by peroxynitrite in endothelial cells. J Soc Gynecol Investig. 2004;11(7):465-71.
68. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov. 2007;6(8):662-80.
69. Gane J, Stockley R. Mechanisms of neutrophil transmigration across the vascular endothelium in COPD. Thorax. 2012;67(6):553-61.
70. Laskin DL, Kimura T, Sakakibara S, Riley DJ, Berg RA. Chemotactic activity of collagenlike polypeptides for human peripheral blood neutrophils. J Leukoc Biol. 1986;39(3):255-66.
71. Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA, et al. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest. 2006;116(3):753-9.
72. Jia W, Li H, He YW. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood. 2005;106(12):3854-9.
73. Adair-Kirk TL, Atkinson JJ, Broekelmann TJ, Doi M, Tryggvason K, Miner JH, et al. A site on laminin alpha 5, AQARSAASKVKVSMKF, induces inflammatory cell production of matrix metalloproteinase-9 and chemotaxis. J Immunol. 2003;171(1):398-406.
74. The COPD foundation: About COPD [Internet]. [cited 2012 Jan 4]. Available from: http://www.copdfoundation.org/PatientsCaregivers/AboutCOPD/tabid/81/language/en-US/Default.aspx.
75. Miller C, George S, Niklason L. Developing a tissue-engineered model of the human bronchiole. Journal of Tissue Engineering and Regenerative Medicine. 2010;4(8):619-27.
76. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, et al. Tissue-engineered lungs for in vivo implantation. Science. 2010;329(5991):538-41.
77. Wu QD, Wang JH, Bouchier-Hayes D, Redmond HP. Neutrophil-induced transmigration of tumour cells treated with tumour-conditioned medium is facilitated by granulocytemacrophage colony-stimulating factor. Eur J Surg. 2000;166(5):361-6.
78. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10(15):4895-900.
79. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene. 2006;25(14):2105-12.
80. Orr FW, Warner DJ. Effects of systemic complement activation and neutrophil-mediated pulmonary injury on the retention and metastasis of circulating cancer cells in mouse lungs. Lab Invest. 1990;62(3):331-8.
81. Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, et al. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer. 2011;129(4):847-58.
82. Lee WL, Downey GP. Leukocyte elastase: physiological functions and role in acute lung injury. Am J Respir Crit Care Med. 2001;164(5):896-904.
83. Vayrynen JP, Vornanen J, Tervahartiala T, Sorsa T, Bloigu R, Salo T, et al. Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. Int J Cancer. 2011 Sept 14. [Epub ahead of print].
84. Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 2011;179(3):1455-70.
85. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. Faseb J. 2005;19(2):234-6.
86. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res. 2005;65(19):8896-904.
87. Sandhu JK, Privora HF, Wenckebach G, Birnboim HC. Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model. Am J Pathol. 2000;156(2):509-18.
88. Jablonska E, Puzewska W, Marcinczyk M, Grabowska Z, Jablonski J. iNOS expression and NO production by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz). 2005;53(2):175-9.
89. D'Alessandro T, Prasain J, Benton MR, Botting N, Moore R, Darley-Usmar V, et al. Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils. J Nutr. 2003;133(11 Suppl 1):3773S-7S.
90. Dissemond J, Weimann TK, Schneider LA, Schneeberger A, Scharffetter-Kochanek K, Goos M, et al. Activated neutrophils exert antitumor activity against human melanoma cells: reactive oxygen species-induced mechanisms and their modulation by granulocytemacrophage-colony-stimulating factor. J Invest Dermatol. 2003;121(4):936-8.
91. Haqqani AS, Sandhu JK, Birnboim HC. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia. 2000;2(6):561-8.
92. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, et al. Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol. 2007;26(2):141-6.
93. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol. 2000;34(3):185-94.
94. Campbell NE, Kellenberger L, Greenaway J, Moorehead RA, Linnerth-Petrik NM, Petrik J. Extracellular matrix proteins and tumor angiogenesis. J Oncol. Epub 2010 Jun 29.
95. Loike JD, el Khoury J, Cao L, Richards CP, Rascoff H, Mandeville JT, et al. Fibrin regulates neutrophil migration in response to interleukin 8, leukotriene B4, tumor necrosis factor, and formyl-methionyl-leucyl-phenylalanine. J Exp Med. 1995;181(5):1763-72.
96. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-9.
97. Brabek J, Mierke CT, Rosel D, Vesely P, Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal. 2010;8:22.
98. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008;27(4):691-705.
99. Nicola A, Hanania MC. Antiinflammatory Therapy in COPD: American college of chest physicians [Internet]. [cited 2012 Jan 4] Available from: http://www.chestnet.org/accp/pccsu/antiinflammatory-therapy-copd?page=0,3PCCSU
100. Cazzola M, Hanania NA. The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(4):345-54.
101. Beeh KM, Glaab T. Is there a role for antiinflammatory treatment in COPD? COPD. 2009;6(5):395-403.
102. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-9.
103. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563-71.
104. Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10(5):365-76.
105. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J. 2009;30(23):2838-44.
106. Kitamoto S, Egashira K, Takeshita A. Stress and vascular responses: anti-inflammatory therapeutic strategy against atherosclerosis and restenosis after coronary intervention. J Pharmacol Sci. 2003;91(3):192-6.
107. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer. 2003;88(6):803-7.
108. Rayburn ER, Ezell SJ, Zhang R. Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol. 2009;1(1):29-43.
109. Rizzo A, Cengel KA. Anti-inflammatory therapy for pancreatic cancer: a sorely needed advance in therapeutics. Cancer Biol Ther. 2008;7(7):1051-2.